These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9827769)

  • 1. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.
    Lee MA; Smith S; Palace J; Matthews PM
    Brain; 1998 Nov; 121 ( Pt 11)():2095-102. PubMed ID: 9827769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy.
    Stevenson VL; Smith SM; Matthews PM; Miller DH; Thompson AJ
    J Neurol; 2002 Feb; 249(2):171-7. PubMed ID: 11985382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: correlations with changes of T2 and magnetization transfer lesion loads.
    Filippi M; Rocca MA; Horsfield MA; Comi G
    J Neurol Sci; 1998 Jun; 158(2):203-8. PubMed ID: 9702692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation.
    O'Riordan JI; Gawne Cain M; Coles A; Wang L; Compston DA; Tofts P; Miller DH
    Mult Scler; 1998 Oct; 4(5):408-12. PubMed ID: 9839300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis.
    Giugni E; Pozzilli C; Bastianello S; Gasperini C; Paolillo A; Koudriavtseva T; Frontoni M; Farina D; Bozzao L
    Mult Scler; 1997 Aug; 3(4):221-5. PubMed ID: 9372503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
    Miller DH; Grossman RI; Reingold SC; McFarland HF
    Brain; 1998 Jan; 121 ( Pt 1)():3-24. PubMed ID: 9549485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F; Scheltens P; Frequin ST; Nauta JJ; Tas MW; Valk J; Hommes OR
    AJR Am J Roentgenol; 1992 Nov; 159(5):1041-7. PubMed ID: 1414773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
    Gasperini C; Pozzilli C; Bastianello S; Giugni E; Horsfield MA; Koudriavtseva T; Galgani S; Paolillo A; Haggiag S; Millefiorini E; Fieschi C
    J Neurol Neurosurg Psychiatry; 1999 Nov; 67(5):579-84. PubMed ID: 10519861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.
    van Walderveen MA; Truyen L; van Oosten BW; Castelijns JA; Lycklama à Nijeholt GJ; van Waesberghe JH; Polman C; Barkhof F
    Arch Neurol; 1999 Mar; 56(3):345-51. PubMed ID: 10190826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
    Molyneux PD; Filippi M; Barkhof F; Gasperini C; Yousry TA; Truyen L; Lai HM; Rocca MA; Moseley IF; Miller DH
    Ann Neurol; 1998 Mar; 43(3):332-9. PubMed ID: 9506550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study.
    Filippi M; Inglese M; Rovaris M; Sormani MP; Horsfield P; Iannucci PG; Colombo B; Comi G
    Neurology; 2000 Oct; 55(7):940-6. PubMed ID: 11061248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.
    Nijeholt GJ; van Walderveen MA; Castelijns JA; van Waesberghe JH; Polman C; Scheltens P; Rosier PF; Jongen PJ; Barkhof F
    Brain; 1998 Apr; 121 ( Pt 4)():687-97. PubMed ID: 9577394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.
    Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K
    Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.
    De Stefano N; Matthews PM; Fu L; Narayanan S; Stanley J; Francis GS; Antel JP; Arnold DL
    Brain; 1998 Aug; 121 ( Pt 8)():1469-77. PubMed ID: 9712009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study.
    Sinnecker T; Mittelstaedt P; Dörr J; Pfueller CF; Harms L; Niendorf T; Paul F; Wuerfel J
    Arch Neurol; 2012 Jun; 69(6):739-45. PubMed ID: 22351849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?
    Lee MA; Smith S; Palace J; Narayanan S; Silver N; Minicucci L; Filippi M; Miller DH; Arnold DL; Matthews PM
    Brain; 1999 Jul; 122 ( Pt 7)():1261-70. PubMed ID: 10388792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis.
    Parry A; Clare S; Jenkinson M; Smith S; Palace J; Matthews PM
    J Neurol; 2002 Sep; 249(9):1279-86. PubMed ID: 12242554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.